U2Bio Co., Ltd. (KOSDAQ:221800)

U2Bio Statistics

Total Valuation

U2Bio has a market cap or net worth of KRW 60.68 billion. The enterprise value is 30.73 billion.

Market Cap	60.68B
Enterprise Value	30.73B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

U2Bio has 13.54 million shares outstanding. The number of shares has increased by 0.55% in one year.

Current Share Class	13.54M
Shares Outstanding	13.54M
Shares Change (YoY)	+0.55%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	53.17%
Owned by Institutions (%)	n/a
Float	5.11M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.37
PB Ratio	1.81
P/TBV Ratio	1.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-10.29
EV / Sales	1.20
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-47.44

Financial Position

The company has a current ratio of 6.07, with a Debt / Equity ratio of 0.01.

Current Ratio	6.07
Quick Ratio	5.92
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.68
Interest Coverage	-62.81

Financial Efficiency

Return on equity (ROE) is -8.51% and return on invested capital (ROIC) is -110.64%.

Return on Equity (ROE)	-8.51%
Return on Assets (ROA)	-3.40%
Return on Invested Capital (ROIC)	-110.64%
Return on Capital Employed (ROCE)	-6.65%
Weighted Average Cost of Capital (WACC)	3.62%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.56
Inventory Turnover	23.36

Taxes

In the past 12 months, U2Bio has paid 1.54 billion in taxes.

Income Tax	1.54B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +62.59% in the last 52 weeks. The beta is -0.12, so U2Bio's price volatility has been lower than the market average.

Beta (5Y)	-0.12
52-Week Price Change	+62.59%
50-Day Moving Average	4,867.50
200-Day Moving Average	3,797.35
Relative Strength Index (RSI)	43.37
Average Volume (20 Days)	1,538,252

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, U2Bio had revenue of KRW 25.59 billion and -2.99 billion in losses. Loss per share was -265.81.

Revenue	25.59B
Gross Profit	5.20B
Operating Income	-2.50B
Pretax Income	-1.45B
Net Income	-2.99B
EBITDA	-1.73B
EBIT	-2.50B
Loss Per Share	-265.81

Balance Sheet

The company has 30.39 billion in cash and 437.74 million in debt, with a net cash position of 29.95 billion or 2,211.10 per share.

Cash & Cash Equivalents	30.39B
Total Debt	437.74M
Net Cash	29.95B
Net Cash Per Share	2,211.10
Equity (Book Value)	33.59B
Book Value Per Share	2,975.62
Working Capital	35.11B

Cash Flow

In the last 12 months, operating cash flow was -634.30 million and capital expenditures -13.44 million, giving a free cash flow of -647.74 million.

Operating Cash Flow	-634.30M
Capital Expenditures	-13.44M
Free Cash Flow	-647.74M
FCF Per Share	-47.82

Margins

Gross margin is 20.33%, with operating and profit margins of -9.77% and -11.67%.

Gross Margin	20.33%
Operating Margin	-9.77%
Pretax Margin	-5.66%
Profit Margin	-11.67%
EBITDA Margin	-6.76%
EBIT Margin	-9.77%
FCF Margin	n/a

Dividends & Yields

U2Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.55%
Shareholder Yield	-0.55%
Earnings Yield	-4.92%
FCF Yield	-1.07%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on February 23, 2023. It was a forward split with a ratio of 4.

Last Split Date	Feb 23, 2023
Split Type	Forward
Split Ratio	4

Scores

U2Bio has an Altman Z-Score of 3.68 and a Piotroski F-Score of 1.

Altman Z-Score	3.68
Piotroski F-Score	1